Hematology

Top news of the week from Specialty Pharmacy Times.

Vemurafenib is a kinase inhibitor indicated to treat patients with Erdheim-Chester disease with BRAF V600 mutations.

Vemurafenib (Zelboraf) receives priority review for Erdheim-Chester Disease.

Officials with the FDA have extended the approval of vemurafenib (Zelboraf, Genentech) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare blood cancer, making it the first approved treatment for ECD.

Novel drug causes apoptosis in leukemia cells, while leaving healthy blood cells unscathed.

PPARγ agonists may improve outcomes for patients with acute myeloid leukemia.

Patients undergoing chemotherapy can use Emend with other antiemetic medicines to prevent chemotherapy-related nausea and vomiting.

Patients undergoing chemotherapy can use Emend with other antiemetic medicines to prevent CINV.

Targeting RNA methylation could treat acute myeloid leukemia.

The approval of tisagenlecleucel (Kymriah) brings in a new era of drug reimbursement.

Patients with peripheral neuropathy may experience pain, numbness, and tingling in the hands and feet, despite cessation of chemotherapy.

A blood cancer drug may kill certain esophageal cancer cells.

Clinical holds placed on Keytruda, Opdivo trials due to adverse event concerns.

Bristol-Myers Squibb and Celgene announce FDA clinical trial holds of PD-1 inhibitors being studied in multiple myeloma.

A patient with cancer died after treatment with a gene-edited allogeneic CAR T-cell treatment.

Leaky blood vessels in bone marrow can lead to chemotherapy failure in acute myeloid leukemia.

Top articles of the week from The American Journal of Pharmacy Benefits.

Clinical trial holds were placed on pembrolizumab to treat multiple myeloma following adverse event concerns.

Pembrolizumab (Keytruda) combination therapy may increase mortality risk among multiple myeloma patients.

High-dose vitamin C found to revert leukemia stem cells with a specific mutation back to normal cells.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

FDA to evaluate obinutuzumab (Gazyva) in combination with chemotherapy for patients with previously untreated follicular lymphoma.

A decision on the approval of obinutuzumab is expected by December 23, 2017.

Top news of the week from Specialty Pharmacy Times.

A first-in-class selective retinoic acid receptor alpha agonist is being tested in phase 2 clinical trials for acute myeloid leukemia and myelodysplastic syndrome.

T cell responses in different tumor models are fundamentally similar.

Brandon Shank, PharmD, MPH, BCOP, discusses how pharmacists work with patients undergoing chemotherapy through transitions of care.

Study finds greater rate of opioid prescribing among cancer survivors 10 or more years past their cancer diagnosis.

FDA approves inotuzumab ozogamicin for relapsed or refractory B-cell precursor ALL.